Find information on thousands of medical conditions and prescription drugs.

Ceftriaxone

Ceftriaxone (trade name Rocephin®) is a third-generation cephalosporin antibiotic. Ceftriaxone is frequently used in combination with azithromycin for the treatment of community-acquired pneumonia. It is also a choice drug for treatment of bacterial meningitis. Rocephin is manufactured by Hoffmann-La Roche pharmaceuticals. The usual starting dose is 2 grams IV daily. There need not be any adjustment in dosing for renal or liver function. more...

Home
Diseases
Medicines
A
B
C
Cabergoline
Caduet
Cafergot
Caffeine
Calan
Calciparine
Calcitonin
Calcitriol
Calcium folinate
Campath
Camptosar
Camptosar
Cancidas
Candesartan
Cannabinol
Capecitabine
Capoten
Captohexal
Captopril
Carbachol
Carbadox
Carbamazepine
Carbatrol
Carbenicillin
Carbidopa
Carbimazole
Carboplatin
Cardinorm
Cardiolite
Cardizem
Cardura
Carfentanil
Carisoprodol
Carnitine
Carvedilol
Casodex
Cataflam
Catapres
Cathine
Cathinone
Caverject
Ceclor
Cefacetrile
Cefaclor
Cefaclor
Cefadroxil
Cefazolin
Cefepime
Cefixime
Cefotan
Cefotaxime
Cefotetan
Cefpodoxime
Cefprozil
Ceftazidime
Ceftriaxone
Ceftriaxone
Cefuroxime
Cefuroxime
Cefzil
Celebrex
Celexa
Cellcept
Cephalexin
Cerebyx
Cerivastatin
Cerumenex
Cetirizine
Cetrimide
Chenodeoxycholic acid
Chloralose
Chlorambucil
Chloramphenicol
Chlordiazepoxide
Chlorhexidine
Chloropyramine
Chloroquine
Chloroxylenol
Chlorphenamine
Chlorpromazine
Chlorpropamide
Chlorprothixene
Chlortalidone
Chlortetracycline
Cholac
Cholybar
Choriogonadotropin alfa
Chorionic gonadotropin
Chymotrypsin
Cialis
Ciclopirox
Cicloral
Ciclosporin
Cidofovir
Ciglitazone
Cilastatin
Cilostazol
Cimehexal
Cimetidine
Cinchophen
Cinnarizine
Cipro
Ciprofloxacin
Cisapride
Cisplatin
Citalopram
Citicoline
Cladribine
Clamoxyquine
Clarinex
Clarithromycin
Claritin
Clavulanic acid
Clemastine
Clenbuterol
Climara
Clindamycin
Clioquinol
Clobazam
Clobetasol
Clofazimine
Clomhexal
Clomid
Clomifene
Clomipramine
Clonazepam
Clonidine
Clopidogrel
Clotrimazole
Cloxacillin
Clozapine
Clozaril
Cocarboxylase
Cogentin
Colistin
Colyte
Combivent
Commit
Compazine
Concerta
Copaxone
Cordarone
Coreg
Corgard
Corticotropin
Cortisone
Cotinine
Cotrim
Coumadin
Cozaar
Crestor
Crospovidone
Cuprimine
Cyanocobalamin
Cyclessa
Cyclizine
Cyclobenzaprine
Cyclopentolate
Cyclophosphamide
Cyclopropane
Cylert
Cyproterone
Cystagon
Cysteine
Cytarabine
Cytotec
Cytovene
Isotretinoin
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

It is one of the newest antibiotics on the market and is particularly effective against respiratory infections.

Ceftriaxone can be used to cover gram-positive organisms, but this drug does not cover Staphylococcus Aureus. For this organism, nafcillin is best to use.

Side Effects include:

  • diarrhea
  • stomach pain
  • upset stomach
  • vomiting

Read more at Wikipedia.org


[List your site here Free!]


Levofloxacin Vs. Ceftriaxone And Erythromycin Followed By Clarithromycin And Amoxicillin/Clavulanate In Serious Community-Acquired Pneumonia - Abstract
From CHEST, 10/1/00 by James B Kahn

James B Kahn, MD(*); Barbara A Wiesinger BSN; Margaret P Oross, BSN, MHSA and William H Olson, PhD. Ortho-McNeil Pharmaceutical, Raritan, NJ.

PURPOSE: This multicenter, randomized, open-label study was designed to compare the efficacy and safety of levofloxacin (LVX) with comparator (C) (ceftriaxone and erythromycin followed by clarithromycin and amoxicillin/clavulanate) in the treatment of serious community-acquired pneumonia (CAP) in adults.

METHODS: Patients were required to be a minimum of 18 years of age and have a diagnosis of serious CAP defined as meeting at least three ATS criteria for hospitalization plus a requirement for mechanical ventilation or other key clinical criteria. A total of 269 patients were enrolled.

RESULTS: Data evaluated to date include 82 patients who completed the posttherapy visit or discontinued according to protocol requirements. The two study arms were generally comparable-by race, gender, age, smoking history, and Apache II scores. The. clinical success rate at posttherapy for clinically evaluable patients was 88.9% in the LVX group compared to 79.2% in the C group. The posttherapy microbiologic eradication rate in the microbiologically evaluable population was 85.7% in the LVX group and 85.7% in the C group. No resistance to LVX was observed. Resistance to the control arm drugs was as follows: ceftriaxone (6.3%), erythromycin (11.1%), clarithromycin (9.4%), and amoxicillin/ clavulanate (12.9%). Adverse events were similar among treatment groups. In LVX-treated patients, constipation, and insomnia were reported more frequently than in C-treated patients, while nausea and diarrhea occurred more frequently in C-treated patients. Six patients (1-LVX, 5-C) were discontinued from the study due to an adverse event. Twenty-two patients (10-LVX, 12-C) experienced one or more serious adverse events. The overall mortality rate for these 82 patients was 10.9%, reflective of a seriously ill population.

CONCLUSION: While there were too few patients to demonstrate statistical equivalence, results from this interim report indicate that LVX 500mg q24h appears at least as effective as traditional combination therapy in the treatment of serious CAP. Complete results from this trial will be presented.

CLINICAL IMPLICATIONS: Levofloxacin is safe and effective in the treatment of hospitalized patients in serious CAP.

COPYRIGHT 2000 American College of Chest Physicians
COPYRIGHT 2001 Gale Group

Return to Ceftriaxone
Home Contact Resources Exchange Links ebay